U.S. clinical research company Charles River Laboratories International had agreed to buy China's WuXi PharmaTech (WX.N) for US$1.6 bn to expand its global footprint in contract research and drug development services, according to a report.
The report stated that the sales agreement has been unanimously approved by the boards of directors of both companies.